Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F21%3AA2202CS4" target="_blank" >RIV/61988987:17110/21:A2202CS4 - isvavai.cz</a>

Alternative codes found

RIV/00843989:_____/21:E0109139

Result on the web

<a href="https://www.webofscience.com/wos/woscc/full-record/WOS:000697995200001" target="_blank" >https://www.webofscience.com/wos/woscc/full-record/WOS:000697995200001</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/fphar.2021.733890" target="_blank" >10.3389/fphar.2021.733890</a>

Result language

angličtina

Original language name

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies

Original language description

Immune checkpoint inhibitors (ICIs), especially those targeting the programmed-death 1 (PD-1) receptor and its ligands, have become indispensable agents in solid tumor anti-cancer therapy. Concerning hematological malignancies, only nivolumab and pembrolizumab have been approved for the treatment of relapsed and refractory classical Hodgkin lymphoma and primary mediastinal large B cell lymphoma to date. Nevertheless, clinical research in this field is very active. The mechanism of action of ICIs is based on unblocking the hindered immune system to recognize and eliminate cancer cells, but that also has its costs in the form of ICI-specific immune related adverse events (irAEs), which can affect any organ system and can even be lethal. In this article, we have reviewed all prospective blood cancer clinical trials investigating ICIs (both monotherapy and combination therapy) with available toxicity data with the purpose of determining the incidence of irAEs in this specific setting and to offer a brief insight into their management, as the use of immune checkpoint blockade is not so frequent in hemato-oncology.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30102 - Immunology

Project

<a href="/en/project/NV17-30089A" target="_blank" >NV17-30089A: In-depth genomic analysis of residual clone in multiple myeloma: approach for individualized targeted therapy</a><br>

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2021

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Frontiers in Pharmacology

ISSN

1663-9812

e-ISSN

—

Volume of the periodical

12

Issue of the periodical within the volume

srpen 2021

Country of publishing house

CH - SWITZERLAND

Number of pages

14

Pages from-to

1-14

UT code for WoS article

000697995200001

EID of the result in the Scopus database

—